Fourth International DTRF
Desmoid Tumor Research Workshop
September 24, 2017

(revised 4.4.17)

Participant Profiles

Benjamin Alman, MD, Professor & Chair, Orthopaedic Surgery, Duke University

Dr. Alman is an orthopaedic clinician-scientist, whose research focuses on understanding role of developmentally important processes in pathologic and reparative process involving the musculoskeletal system. The long-term goal of his work is to use this knowledge to identify improved therapeutic approaches to orthopaedic disorders. He makes extensive use of genetically modified mice to model human disease, and has used this approach to identify new drug therapies for musculoskeletal tumors and to improve the repair process in cartilage, skin, and bone. He also works on cellular heterogeneity in sarcomas, and has identified a subpopulation of tumor initiating cells in musculoskeletal tumors. In this work, he also has identified specific cell populations that are responsible for joint and bone development. He has was recently recruited from the University of Toronto to Duke University to chair the department of orthopaedics, which was established in 2010, and includes a large musculoskeletal research component. He has half his time protected for his research work. Dr. Alman is the Principal Investigator in the DTRF-funded collaborative project, "Collaboration for a Cure: Identifying new therapeutic targets for desmoid tumors." Profile here.

Steven Attia, DO, Assistant Professor of Oncology, Mayo Clinic

Dr. Steven Attia is a medical oncologist at Mayo Clinic in Jacksonville, Florida. He is fellowship trained at the University of Wisconsin. His sole clinical and research focus is patients with desmoid tumor, sarcomas of soft tissue and bone including gastrointestinal stromal tumor (GIST), as well as chordoma, epithelioid hemangioendothelioma (EHE) and other locally aggressive or malignant tumors of soft tissue and bone. He is the research chair for the Mayo Clinic Sarcoma Disease Oriented Group. Aside from clinical trials and patient care, Dr. Attia has an interest in optimizing the way patients with rare tumors are discussed. He chairs a first-in-kind, CME accredited, weekly international sarcoma tumor board which he founded in 2010 that connects 10 sarcoma centers in the United States and Europe by videoconference to review challenging cases seen at these centers. Profile here.

Palma Dileo, MD, Consultant Medical Oncologist London Sarcoma Service, University College London Hospitals

Dr. Palma Dileo is Consultant Medical Oncologist on the Sarcoma Unit at University College Hospital, UCLH NHS Trust, specialising exclusively in the management of soft tissue and bone sarcomas. The Sarcoma Unit at UCLH, together with the Sarcoma Unit at the Royal National Orthopaedic Hospital, is the London Sarcoma Service (www.londonsarcoma.org) which offers a comprehensive clinical service to patients of all ages with sarcoma at all sites of the body. She continued to provide patient care since 1996 (general oncology), with more emphasis on sarcoma and rare tumours starting from 1998. She completed her training at the Istituto Nazionale Tumori of Milan, Italy and at Dana-Farber Cancer Institute, Boston, USA. From 2006 to 2010 she has been Associate Physician, Medical Oncology, Istituto Nazionale Tumori, Milan working in the Sarcoma Team. She has a strong interest in early phase clinical trials and is a co-investigator for a number of clinical trials in sarcoma. She is a member of the EORTC Soft Tissue and Bone Sarcoma Group and ASCO. Profile here.

Bernd Kasper, MD, PhD, Professor, Mannheim University Medical Center, Interdisciplinary Tumor Center, Sarcoma Unit

Prof. Bernd Kasper studied Medicine at the University of Heidelberg. In 2001, he finalised his thesis at the German Cancer Research Centre (DKFZ) dealing with new treatment strategies for chronic myelogenous leukaemia patients using the tyrosine kinase inhibitor imatinib. To deepen his training, he stayed in London (Imperial College School of Medicine, Hammersmith Hospital, Department of Haematology) and Brussels (Jules Bordet Institute, Medical Oncology Clinic). In 2007 and 2008, he specialized in Internal Medicine and Medical Haematology/Oncology at the Department of Internal Medicine V at the University of Heidelberg. Currently, he works together with Prof. Peter Hohenberger at the Sarcoma Unit of the Interdisciplinary Tumor Center Mannheim (ITM) at the Mannheim University Medical Center, University of Heidelberg. Since 2011, he is the Leading Physician and coordinator of the ITM. Since 2002, his special interest lies in the treatment of patients with bone and soft tissue sarcomas including GIST and desmoids. He is head of the study center of the German Interdisciplinary Sarcoma Group (GISG) and is active in national and international study groups (AIO, EORTC). Profile here.

Yoshihiro Nishida, MD, PhD, Chairman, Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine

Dr. Yoshihiro Nishida is Associate Professor, Chairman, Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine. He has published more than 100 articles on Orthopaedic Oncology and basic research area. His present specialty is surgical and conservative treatment for patients with bone and soft tissue tumors, and doing translational and clinical research. He graduated from Nagoya University School of Medicine, Japan, in 1988. He was selected as a traveling fellow of Japanese Orthopaedic Association—American Orthopaedic association in 2005. He has been a PI of "Study for understanding of current status and established of treatment guideline for patients with extra-peritoneal desmoid tumors" which is selected by Health, Labour, and Welfare Ministry of Japan. Profile here.

Jean Paty, PhD, Patient-Centered Endpoints, QuintilesIMS

Jean is an acknowledged leader in the effective strategies and practices of capturing patient perspective data for use in the clinical development and commercial success of new medical products. He has not only published extensively in the areas of Patient Reported Outcomes (PRO) and electronic PRO (ePRO), but also on the regulatory guidance for development and implementation of ePRO. He has worked closely with the international industry and regulatory agencies on ePRO best practices. Dr. Paty's work is well-referenced in a wide variety of peer-reviewed journals and in numerous conferences and events, where he has presented his findings on the scientific, clinical, and regulatory implications of Clinical Outcome Assessment (COA) data collection in clinical trials. Profile here.

Raphael Pollock, MD, PhD, FACS, Professor and Director, Division of Surgical Oncology, Surgeon in Chief, James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center

Dr. Raphael Pollock is Professor and Director of the Division of Surgical Oncology at the Ohio State University Wexner Medical Center, and holds the Kathleen Wellenreiter Klotz Chair in Cancer Research. He also serves at Surgeon in Chief for the James Comprehensive Cancer Center and the Ohio State University Health System. Dr. Pollock's work focuses on soft tissue sarcoma. His laboratory research activities are examining multiple facets of the molecular drivers underlying soft tissue sarcoma inception focus on soft tissue sarcoma, a rare cancer in adults but rather prevalent in children. He has

published widely on sarcoma surgery and treatment, and his funded research includes sarcoma molecular biology and the development of novel therapeutics for this group of diseases. His laboratory work involves the discovery of oncogenes and tumor suppressor genes in soft tissue sarcoma. He is principal investigator of an $11.5 million National Cancer Institute (NCI) grant to support collaborative sarcoma translational research. The NCI Specialized Programs of Research Excellence (SPORE) grant, awarded to the Sarcoma Alliance for Research for Collaboration, represents the largest award ever to study sarcoma.Profile here.

Silvia Stacchiotti, Medical Oncologist, Fondazione IRCCS Istituto Nazionale Dei Tumori

A medical oncologist, dr. S. Stacchiotti, works in the Adult mesenchymal and rare tumor medical treatment unit, Cancer Medicine Department, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milano, Italy.

Dr Stacchiotti clinical and research activities focus on adult soft tissue and bone sarcomas, including gastrointestinal stromal tumors (GIST). She is involved in all institutional research activities on sarcoma, with a special focus on very uncommon subtypes such as chordoma, chondrosarcoma, giant cell tumor of the bone, alveolar soft part sarcoma, clear cell sarcoma, DFSP, desmoid, solitary fibrous tumor, vascular tumor, PVNS, PEComa. She is the Principal Investigator and Coinvestigator of several trials on Sarcoma and GIST. She is a member of the Italian Sarcoma Group, a national cooperative group for clinical and translational research on soft tissue and bone sarcomas, and is a member of the EORTC Soft Tissue & Bone Sarcoma Group. She collaborates to the Italian Network on Rare Tumors, a collaborative effort among Italian cancer centers, which tries to exploit distant patient sharing in order to improve quality of care and diminish health migration for rare solid cancers. She is a member of ESMO (European Society for Medical Oncology), Connective Tissue Oncology Society (CTOS) and of ASCO (America Society of Medical Oncology). She is a member of the advisory board of the Chordoma Foundation and of Desmoid Tumor Research Foundation. She is included in the list of European Medical Agency (EMA) external expert. She serves as associate Editor of the European Journal of Cancer and of Sarcoma Journal.

She has authored more than 100 scientific publications on sarcoma.

Born in 1968, dr Silvia Stacchiotti received his medical degree in 1993 in Milan, and trained at the INT. She is certified in Clinical Oncology.

Nadage Corradini, Pediatric Oncologist, IHOP Léon BERARD Centre

Dr. Nadage Corradini is a member of EpSSG group and SFCE and Secretary of SOS-Desmoid French Association.

Matthew van de Rijn, MD, PhD, Professor, Department of Pathology, Stanford University Medical Center

Matt van de Rijn received his MD and PhD degrees from the University of Amsterdam, the latter based on his research at the Netherlands Cancer Institute and the DANA Farber Cancer Institute. After a postdoctoral fellowship at Stanford University he completed his residency training in surgical pathology and joined the faculty at the University of Pennsylvania. In 1998 he returned to Stanford where he is now a Professor in Pathology. His research has focused on sarcoma

and he reported the first major gene expression profiling study on sarcomas in 2002. The identification of a novel translocation involving CSF1 in PVNS resulted in several ongoing clinical trials. In addition his group discovered a novel diagnostic marker for GIST (DOG1). Gene expression profiling studies also led to the investigation of the role of macrophages in leiomyosarcoma (LMS) and GIST with an opportunity to develop therapeutic targets for these tumors. In addition to his work on LMS and GIST he has performed gene expression profiling studies on Desmoid Tumors to study the biology that underlies the aggressive behavior of these tumors, to develop novel diagnostic markers and discover novel therapeutic targets.

Dr. van de Rijn is Principal Investigator of the DTRF-funded study, "Next generation sequencing approach to desmoid tumors." His lab uses next generation sequencing approaches to study gene expression profiles of desmoid tumors, scars and other fibroblastic lesions with the goal of identifying diagnostic and prognostic markers. Profile here.

Yuhong Zhou, MD, Professor of Sarcoma & Oncologist, Zhongshan Hospital, Fudan University